Establishing an Integrated Dementia Treatment System

Seoul St. Mary's Hospital has reached 200 cases of antibody treatment aimed at slowing the progression of Alzheimer's disease. The hospital explained that both the Department of Neurology and the Department of Psychiatry operate their own independent prescription systems, establishing an integrated care system for early-stage Alzheimer's patients that covers everything from diagnosis to medication and safety management.


As of May, Seoul St. Mary's Hospital announced on the 1st that it had achieved 200 cases of antibody treatment for Alzheimer's disease. Unlike conventional symptom-relief therapies, Alzheimer's antibody treatment is considered a disease-modifying therapy, as it removes amyloid beta protein, one of the causes of the disease, thereby slowing its progression.


Amyloid PET images showing amyloid accumulation. From left, normal brain, Alzheimer's disease. Seoul St. Mary's Hospital

Amyloid PET images showing amyloid accumulation. From left, normal brain, Alzheimer's disease. Seoul St. Mary's Hospital

View original image

Alzheimer's disease is a degenerative brain disorder in which abnormal accumulation of beta-amyloid and tau proteins in the brain damages nerve cells. In Korea, the introduction of antibody therapies targeting amyloid proteins into clinical practice began at the end of 2024, marking the start of a shift in the treatment paradigm.


Antibody therapies are known to be most effective in early-stage patients. Accurate diagnosis through amyloid positron emission tomography (PET) scans or cerebrospinal fluid testing is required before administration. In addition, biweekly intravenous infusions and regular brain magnetic resonance imaging (MRI) monitoring are necessary, making specialized medical staff and safety management systems essential.


Seoul St. Mary's Hospital operates a system in which the Departments of Neurology and Psychiatry cooperate with the Departments of Radiology, Nuclear Medicine, Laboratory Medicine, and Nursing, managing everything from amyloid PET diagnosis to medication administration and adverse reaction control.


Amyloid-related imaging abnormalities (ARIA), which can occur during treatment, may manifest as brain edema or microhemorrhages, making regular MRI monitoring important. Most cases are asymptomatic and manageable, but in rare instances, serious adverse reactions can occur, requiring monitoring by experienced medical professionals.


Dongwon Yang, Professor of Neurology at Seoul St. Mary's Hospital, said, "Dementia specialists are carefully selecting patients eligible for antibody therapy, and so far, serious side effects have been rare among Korean patients. It has also been confirmed that early-stage patients with lower initial levels of amyloid accumulation tend to respond more quickly to treatment."



Dongwoo Kang, Professor of Psychiatry, stated, "The introduction of anti-amyloid immunotherapies has marked a shift in Alzheimer's disease treatment from symptom management to targeting the pathology of the disease. Precision diagnosis and treatment strategies based on each patient's disease stage and biomarker status are crucial."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing